A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma

Trial Profile

A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Alvocidib (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Large cell carcinoma; Lymphoma; Lymphomatoid granulomatosis; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Sclerosis; Sezary syndrome; T cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 02 May 2013 Planned end date changed from 1 Mar 2007 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top